Potential harms of long-term acne treatment with oral antibiotics

Minh Dao DO  Gary Kelsberg MD  Diana Louden MLib

Clinical Inquiries question
What are the potential harms of long-term acne treatment with oral antibiotics?

Evidence-based answer
Specific evidence attributing adverse effects to long-term acne treatment with oral antibiotics is lacking. However, nausea, vomiting, or diarrhea are seen in 7% of patients taking tetracyclines, 4% taking macrolides, and 2% taking clindamycin. Tetracyclines also cause dizziness, headache, and photosensitivity in 2% of patients (strength of recommendation [SOR] A: based on meta-analyses of randomized controlled trials [RCTs]). In addition, tetracyclines are associated with rare hypersensitivity reactions (pneumonitis, eosinophilic nephritis, serum sickness) and intracranial hypertension (SOR C: based on case reports). Minocycline might increase the risk of systemic lupus erythematosus (SLE), autoimmune hepatitis, and polyarteritis nodosa, generally after 1 year of use (SOR B: based on retrospective cohort and case-control studies). Macrolides are associated with cardiac conduction abnormalities and, rarely, hepatotoxicity. Clindamycin is associated with pseudomembranous colitis (SOR C: based on case reports).

Evidence summary
Physicians most commonly select from 3 classes of medications (tetracyclines, macrolides, and clindamycin) when indicating oral antibiotics for the treatment of acne. The potential harms or adverse effects of this antibiotic use are described below.

Tetracyclines (tetracycline, oxytetracycline, lymecycline, doxycycline, minocycline). A 2012 systematic review of studies of adverse effects largely associated with minocycline divided the types of adverse effects into 3 categories: early dose-related effects on single organ systems (vestibular, gastrointestinal, dermatologic), hypersensitivity reactions (pneumonitis, eosinophilic nephritis, serum sickness), and autoimmune disorders (SLE, autoimmune hepatitis, polyarteritis nodosa).1 While minocycline commonly produced adverse effects in single organ systems (332 of 1906 patients [17.4%] in 29 RCTs), it did not often result in discontinuation of the drug (79 of 2143 patients [3.7%] in 34 RCTs withdrew as a result of adverse effects), but there were more withdrawals due to adverse effects than with placebo (relative risk of 1.08; 95% CI 1.03 to 1.13). Furthermore, a 2006 systematic review of placebo-controlled RCTs of oral antibiotics for acne reported that tetracyclines produced mild gastrointestinal adverse effects in 7% of participants, dizziness and headache in 2%, and photosensitivity in 2%.2 In the 2012 systematic review, the authors identified 56 cases of hypersensitivity disorders associated with tetracyclines over 40 years, and 3 cases of serum sickness.1 They also found a retrospective cohort study and 3 case-control studies evaluating autoimmune disorders associated with minocycline, which showed increased risk of SLE (2.6 to 8.5 times) and liver dysfunction (2.1 times), particularly with use longer than 1 year (Table 1).1 A systematic review of intracranial hypertension induced by acne medication–associated cases of pseudotumor cerebri (PTC) with tetracycline use, with symptoms manifesting in hours to months.3 Doxycycline and minocycline were also associated with PTC, but those reported cases were few. Most cases of PTC induced by minocycline occurred in teenagers and young adults.

Macrolides (erythromycin, azithromycin). Two systematic reviews of antibiotic treatments for acne,4,5 both predominantly involving teenagers and young adult populations, described gastrointestinal symptoms (nausea, vomiting, and abdominal pain) as the most common adverse effects of erythromycins (incidence of 4% with erythromycin stearate and 20% with erythromycin base). A meta-analysis6 of 6 RCTs (N=906) comparing oral azithromycin and oral doxycycline for acne reported severe diarrhea necessitating discontinuation in 4 patients. One systematic review of 22 mostly open-label studies evaluating the efficacy of azithromycin in acne treatment found few gastrointestinal adverse effects and noted the absence of photosensitivity.6 The authors of the 2 previously mentioned meta-analyses5,4 also described cardiac conduction abnormality as a rare adverse effect, based on case reports (incidence specific to acne patients not supplied). A retrospective cohort study evaluating use of oral erythromycin in middle-aged adults found that it was associated with a higher risk of sudden cardiac death.7 The authors reviewed 1249943 person-years of follow-up of oral erythromycin use in a Tennessee Medicaid population (average age 45 years; 25% of the cohort older than 65 years) and found 1.2 deaths per 1000 person-years (incidence rate ratio of 2.01; 95% CI 1.08 to 3.75). However, erythromycin use for acne was not specified. Patients concurrently taking cytochrome P450 3A inhibitors with oral erythromycin

Vol 66: SEPTEMBER | SEPTEMBRE 2020  •  Canadian Family Physician | Le Médecin de famille canadien 669
Table 1. Possible adverse effects associated with acne treatment with oral tetracycline, oxytetracycline, minocycline, and erythromycin: Statistically significant adverse effects are highlighted in bold.

<table>
<thead>
<tr>
<th>DRUG</th>
<th>ADVERSE EFFECT</th>
<th>STUDY TYPE</th>
<th>NO. OF PARTICIPANTS</th>
<th>RISK (95% CI)</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minocycline</td>
<td>SLE</td>
<td>Retrospective cohort</td>
<td>97,694</td>
<td>• HR = 2.64 (1.51 to 4.66)</td>
<td>• Prevalence of 8.8 cases per 100,000 patient-years</td>
</tr>
<tr>
<td>Minocycline</td>
<td>SLE</td>
<td>Case-control</td>
<td>875</td>
<td>• OR = 4.23 (1.03 to 42.74)</td>
<td>NA</td>
</tr>
<tr>
<td>Minocycline or other tetracyclines</td>
<td>SLE</td>
<td>Case-control</td>
<td>27,688</td>
<td>• 8.5 (2.1 to 3.5) for minocycline</td>
<td>Absolute risk for tetracyclines is 52.8 cases per 100,000 prescriptions</td>
</tr>
<tr>
<td>Minocycline, tetracycline or oxytetracycline, and erythromycin</td>
<td>Liver dysfunction</td>
<td>Case-control</td>
<td>29,332</td>
<td>• ORadj = 2.10 (1.30 to 3.40) for minocycline</td>
<td>Incidence was 1.04 cases per 10,000 exposed person-months with minocycline, and 0.69 cases per 10,000 exposed person-months with tetracycline or oxytetracycline</td>
</tr>
</tbody>
</table>

HR—hazard ratio, ORadj—adjusted odds ratio, NA—not applicable, OR—odds ratio, SLE—systemic lupus erythematosus. Data from Garner et al.1

had a 5-fold increased risk of cardiac death.7 Based on case reports, macrolides are rarely associated with hepatotoxicity (incidence not supplied).8

Clindamycin. The aforementioned systematic review found more mild diarrhea in a clindamycin group than the placebo group, though it was not significant. Additionally, pseudomembranous colitis occurred in 1 patient (N = 42).2

Recommendations from others

The 2016 American Academy of Dermatology guidelines for the treatment of acne recommended that systemic antibiotics for moderate to severe acne should be used for the shortest possible duration, with reevaluation at 3 to 4 months, in order to minimize antibiotic resistance.8

Dr Dao is a resident family physician at the Valley Family Medicine Clinic in Renton, Wash. Dr Kelsberg is Deputy Editor of FPIN’s Clinical Inquiries and is part of the faculty at the Valley Family Medicine Clinic. Ms Louden is Life Sciences Librarian at the University of Washington in Seattle, Wash.

Competing interests
None declared

Correspondence
Dr Gary Kelsberg: e-mail kelsberg@uw.edu

References

Clinical Inquiries are author-formulated questions that are answered with the best available current evidence, written by family medicine residency faculty and their residents through the Family Physician Inquiries Network. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (www.cebm.net). The Family Physicians Inquiries Network Clinical Inquiries series in Canadian Family Physician is coordinated by Rick Guthmann, MD, MPH, Editor-in-Chief for the series. If interested in submitting questions or writing answers for this series, go to www.fpin.org or e-mail ci@fpin.org.

©Family Physicians Inquiries Network. Used with permission.